摘要
目的观察电子止吐仪联合帕洛诺司琼、阿瑞匹坦及地塞米松防治肺癌患者大剂量顺铂化疗所致呕吐的疗效与安全性。方法222例接受大剂量顺铂化疗的肺癌患者随机分为试验组和对照组,对照组患者使用托烷司琼、阿瑞匹坦及地塞米松防治呕吐,而试验组加用电子止吐仪。比较两组化疗后120h内恶心、呕吐、呃逆及不良反应情况。结果试验组延迟性呕吐和总呕吐发生率均低于对照组(P<0.01),两组不良反应差异无统计学意义(P>0.05)。结论电子止吐仪联合帕洛诺司琼、阿瑞匹坦及地塞米松可有效预防肺癌患者大剂量顺铂化疗所致呕吐。
Objective To observe the antiemetic efficacy and safety of electronic antiemetic instrument with palonosetron, aprepitant and dexamethasone in patients with lung cancer undergoing high-dose cisplatin chemotherapy. Methods A total of 222 patients with lung cancer received the antiemetic measures of palonosetron, aprepitant and dexamethasone (control group) or additional electronic antiemetic instrument (experimental group) during high-dose cisplatin chemotherapy. Nausea, vomiting, hiccup, and adverse reactions were compared between two groups. Results Incidence of delayed and overall vomiting was lower in experimental group than in control group (P<0.01). But adverse reactions were comparable between two groups (P>0.05). Conclusion Combined electronic antiemetic instrument, palonosetron, aprepitant, and dexamethasone can prevent high-dose cisplatin chemotherapy-induced vomiting in patients with lung cancer.
作者
江冠铭
谭钦全
曾溢蕻
林顺欢
刘淳
林钦雄
JIANG Guan-ming;TAN Qin-quan;ZENG Yi-gong;LIN Shun-huan;LIU Chun;LIN Qin-xiong(Department of Oncology Medicine, Dongguan People’s Hospital, Dongguang 523000, China)
出处
《广东医科大学学报》
2019年第4期439-442,共4页
Journal of Guangdong Medical University
关键词
肺癌
顺铂
电子止吐仪
帕洛诺司琼
阿瑞匹坦
lung cancer
cisplatin
electronic antiemetic instrument
palonosetron
aprepitant
